Lianluo Smart (Lianluo Smart) ROCE % : -62.10% (As of Dec. 2020)

View and export this data going back to 2010. Start your Free Trial

What is Lianluo Smart ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Lianluo Smart's annualized ROCE % for the quarter that ended in Dec. 2020 was -62.10%.

Lianluo Smart ROCE % Historical Data

The historical data trend for Lianluo Smart's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lianluo Smart ROCE % Chart

Lianluo Smart Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

ROCE %

Get a 7-Day Free Trial

-79.32

-35.72

-69.82

-227.19

-244.65

Lianluo Smart Semi-Annual Data
	Jun11	Dec11	Jun12	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20
ROCE %	Get a 7-Day Free Trial															-69.13	-252.94	-2,490.00	-168.87	-62.10

Lianluo Smart ROCE % Calculation

Lianluo Smart's annualized ROCE % for the fiscal year that ended in Dec. 2020 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2020 )		(A: Dec. 2019 )		(A: Dec. 2020 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2020 )		(A: Dec. 2019 )		(A: Dec. 2020 )
	=	-2.975	/	( ( (2.334 - 3.233)	+	(6.048 - 2.717) )	/ 2 )
	=	-2.975	/	( (-0.899	+	3.331)	/ 2 )
	=	-2.975	/	1.216
	=	-244.65 %

Lianluo Smart's ROCE % of for the quarter that ended in Dec. 2020 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2020 )		(Q: Jun. 2020 )		(Q: Dec. 2020 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2020 )		(Q: Jun. 2020 )		(Q: Dec. 2020 )
	=	-2.56	/	( ( (8.183 - 3.269)	+	(6.048 - 2.717) )	/ 2 )
	=	-2.56	/	( ( 4.914	+	3.331 )	/ 2 )
	=	-2.56	/	4.1225
	=	-62.10 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2020) EBIT data.

Lianluo Smart (NAS:LLIT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Lianluo Smart ROCE % Related Terms

Thank you for viewing the detailed overview of Lianluo Smart's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Lianluo Smart (Lianluo Smart) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lianluo Smart Ltd (NAS:LLIT) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 10 Baifuquan Roa, Room 611, 6th Floor, BeiKong Technology Building, Changping District, Beijing, CHN, 102200

Website

http://www.lianluosmart.com

Lianluo Smart Ltd design, develop and market medical products and medical components. The company focuses on the business sectors of; Medical Equipment and the provision of Obstructive Sleep Apnea Syndrome (OSAS) diagnostic services. Its products include wearable sleep respiratory devices, medical devices for cardiopulmonary resuscitation, DHR998 Plus, and others. The company sells its products to distributors, hospitals and physical examination centers, and others. All of its revenue is generated from China.